BerGenBio

Selective AXL inhibitors

Home  /  asco

Tag: asco

20222021202020192018201720162015

BerGenBio Reports First-in-Patient Phase 1 Data for BGB324 in Patients with Myeloid Malignancies at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting

July 4, 2016

Promising clinical activity with biologic activity, tolerability, and durability BerGenBio AS ("BerGenBio" or the "Company"),…

Read More

Subscribe to our newsletter

Please remember to confirm your email by clicking on the link provided in the subscription confirmation email. We will save your name and email address with the sole purpose of sending information regarding our latest news and events. By subscribing to BerGenBio’s newsletter you consent to our Privacy Policy and Terms of Use.